RT Journal Article SR Electronic T1 BNT162b2 COVID-19 VACCINATION AND ITS EFFECT ON BLOOD PRESSURE JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.16.21258803 DO 10.1101/2021.06.16.21258803 A1 Toh Leong Tan A1 Sharifah Azura Salleh A1 Zuraidah Che Man A1 Michelle Hwee Peng Tan A1 Rashid Kader A1 Razman Jarmin YR 2021 UL http://medrxiv.org/content/early/2021/06/21/2021.06.16.21258803.abstract AB This study aims to explore the trends of systolic blood pressure (SBP), diastolic BP (DBP), mean arterial pressure (MAP) and pulse pressure (PP) before and 15-minutes after two doses of the BNT162b2 vaccine, which were administered 21 days apart. This vaccine safety active surveillance study was carried out on 15th-16th March (first dose) and 5th-6th April 2021 (second dose), in academic hospital.. Vaccinees above 18 years old, SBP, DBP, MAP and PP pre- and 15 minutes post-vaccination for both doses were analysed. Study outcomes were mean of BP, mean of BP changes, and BP trends measurements. A total of 287 vaccinees were included. A quarter (n=72) had decreased DBP ≥ 10mmHg (mean DBP deceased: 15mmHg, 95%CI: 14-17mmHg) after the first dose, and 12.5% post-second dose (mean DBP decreased: 13mmHg, 95%CI: 12-15mmHg). Post-first dose, 28.6% (n= 82) were found to have widened PP > 40mmHg. After the first dose, those who had elevated and decreased SBP ≥ 20mmHg were 5.2% and 4.9%, respectively. Eleven percent (n = 32) had decreased SBP ≥ 20mmHg post-second dose, nevertheless the psychology effect cannot be ruled out. The BNT162b2 vaccine was generally well tolerated. BP changes after vaccination emphasizes the need for monitoring.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Faculty of Medicine, Universiti Kebangsaan Malaysia, awarded to TLT (Fundamental Fund grant, FF-2021-138). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by UKM Human Ethical Review Board (JEP-2021-302). The active surveillance was carried out as part of COVID-19 vaccination program activities to monitor BNT162b2 vaccination safety among our hospital healthcare workers (HCW). Due to the retrospective nature of this study, it waived the need of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll vaccine-related data that were collected were kept in a secured location and only accessible to authorised personnel. The data that support the findings of this study are available from Toh Leong Tan. However, restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of Toh Leong Tan.